Adcendo is a biotechnology company specializing in the development of first-in-class antibody-drug conjugates (ADCs) aimed at treating cancers with high unmet medical needs. The company is advancing multiple ADC programs into clinical trials to establish clinical proof of concept, focusing on innovative treatments that target specific cancer pathways.